LYEL - Lyell Immunopharma Inc
IEX Last Trade
1.455
-0.005 -0.344%
Share volume: 1,025,531
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$1.46
-0.01
-0.34%
Fundamental analysis
12%
Profitability
0%
Dept financing
3%
Liquidity
75%
Performance
11%
Performance
5 Days
-7.05%
1 Month
-8.23%
3 Months
-45.49%
6 Months
-48.94%
1 Year
-38.30%
2 Year
-76.95%
Key data
Stock price
$1.46
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.18 - $3.26
52 WEEK CHANGE
-$0.38
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO:
Region: US
Website: lyell.com
Employees: 272
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lyell.com
Employees: 272
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
Recent news